Journal article

Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2)

Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, James Sun, Dennis Kirichenko, Michael J Carr, Avinash Sharma, Edmund K Bartlett, Amanda AG Nijhuis, John F Thompson, Tina J Hieken, Lisa Kottschade, Jennifer Downs, David E Gyorki, Emma Stahlie, Alexander van Akkooi, David W Ollila, Jill Frank, Yun Song, Giorgos Karakousis Show all

CANCER | WILEY | Published : 2021

Abstract

BACKGROUND: For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown. METHODS: In a retrospective cohort of SLN-positive adults treated at 21 institutions in Australia, Europe, and the United States from June 2017 to November 2019, the authors evaluated the impact of active surveillance and adjuvant therapy on all-site recurrence-free survival (RFS), isolated no..

View full abstract

Grants

Awarded by Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated comprehensive cancer center


Funding Acknowledgements

This work was supported in part by the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated comprehensive cancer center (P30-CA076292).